About Us
Unlocking the Future of IMID Treatments
Immune-mediated inflammatory diseases, or IMIDs, encompass a wide range of conditions united by common inflammatory and genetic pathways. These commonly known IMIDS are chronic in nature and characterized by substantial and enduring morbidity, affecting millions in the United States alone. Common IMIDs include skin or cutaneous inflammatory diseases such as chronic urticaria (commonly known as hives), atopic dermatitis, and prurigo nodularis; joint or rheumatologic and connective tissue disorders, such as rheumatoid arthritis and systemic lupus erythematosus; gut or gastrointestinal diseases, such as inflammatory bowel disease, including Crohn’s disease and ulcerative colitis; lung or respiratory and allergic airway conditions, such as asthma and allergic rhinitis; and autoimmune neurological diseases such as multiple sclerosis.
Treatment has historically relied heavily on glucocorticoids to manage inflammation. More recently, the landscape has been dominated by injectable biologic agents — such as cytokine-blockade therapies and tumor necrosis factor (TNF) inhibitors — as well as select oral small-molecule therapies, including kinase inhibitors and immunomodulators. In general, these treatments may carry significant limitations, including safety issues (often accompanied by “black box” warnings), risk of infection, inadequate or waning response, immunogenicity, resistance with chronic use, withdrawal/rebound, compliance challenges due to inconvenient or invasive dosing regimens, and high cost — especially for biologics.
We believe that the current landscape remains constrained by an incomplete understanding of the complex pathways driving immune dysfunction, and that there is a continued unmet need for oral, safe, and effective small-molecule therapies for IMIDs.
IMID treatment has faced challenges due to the intricate and multifaceted nature of the inflammatory process. Therapeutic options have often been limited to symptomatic interventions, with varying degrees of effectiveness. One major obstacle has been the lack of a comprehensive understanding of the pathophysiological mechanisms driving immune-mediated inflammation. The biological and molecular complexity of these pathways has made it a formidable task to harness them for therapeutic purposes.
Our mission is to transform the lives of patients with chronic IMIDs through the development of oral, safe and effective small molecule product candidates. Our commitment to addressing the underlying mechanisms that drive IMIDs combines the latest advances in artificial intelligence and machine learning with our team’s extensive experience and expertise to unravel the root causes of chronic inflammation.
We harness the power of artificial intelligence (AI) and machine learning (ML) through our use of InveniAI’s AlphaMeld Platform, we seek to uncover the complex mechanisms driving inflammation in immune-mediated inflammatory diseases (IMIDs). By mining genes, drugs, diseases, symptoms, and processes, we create IMID-focused networks to identify crucial relationships and cause-and-effect connections. This innovative approach results in an extensive target association network comprising thousands of potential targets, drugs, and IMIDs. Developed using AI and ML technology, we believe this network could accelerate discovery, reveal hidden insights, and streamline the regulatory process for future product candidates. We have initially identified two mechanisms that we believe may impact the treatment paradigm for several IMIDs.
Mast cells are central to the inflammation process in many IMIDs. Our lead program, INVA8001, is a highly selective inhibitor of chymase, a key mediator of mast cell-driven inflammation. We believe this approach can impact the treatment of several IMIDs including chronic urticaria, prurigo nodularis, and atopic dermatitis.
Inflammasomes play a crucial role in controlling inflammatory responses. Our second product candidate, INVA8003, targets apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), offering a potential solution for chronic inflammation and the treatment of a number of IMIDs.
Through this approach, we are committed to advancing the field of IMID treatment, delivering hope to patients, and leveraging the power of AI and ML to make discoveries that can change lives. Our dedication to innovation and excellence drives us forward, and we believe in the potential of our approach to make a meaningful difference in the lives of patients with IMIDs.
